Hims & Hers Issues First FY Revenue Outlook at $3.1B-$3.3B
HIMS has more than doubled off its 52-week low of $13.74.
Summary
Hims & Hers provided its first full-year revenue guidance of $3.1 billion to $3.3 billion, a significant milestone that gives investors a concrete top-line target. The company raised its annual forecast on strong subscriber growth, but swung to a second-quarter loss. This follows a turbulent period: a $402.5 million convertible note issuance in May, the Eucalyptus acquisition closing in June, and a July FTC lawsuit alleging improper sharing of health data. The guidance range implies substantial growth from the $1.5 billion revenue run rate implied by recent quarters, suggesting management sees strong momentum despite legal headwinds. The midpoint of $3.2 billion would represent a material step-up in scale, likely driven by expanded telehealth offerings and international reach from Eucalyptus. Investors will watch for margin commentary and any impact from the FTC suit on customer acquisition costs when full earnings are released.
At the time of this announcement, HIMS was trading at $29.49 on NYSE in the Life Sciences sector, with a market capitalization of approximately $7.4B. The 52-week trading range was $13.74 to $65.30. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.